Inclusion Criteria:

        For Part 1 and 2:

          -  The Investigator reviews the medical history, menstrual history, and recent sexual
             activity to decrease the risk for inclusion of a female with an early undetected
             pregnancy

        For Part 1:

          -  Locally advanced or metastatic disease that is intolerant or refractory to standard
             therapy or for which no standard therapy is judged appropriate by the investigator

          -  Participants with solid tumors expressing or likely to expressing EGFR and MUC1,
             including but not limited to lung cancer, squamous esophageal cancer, head and neck
             squamous cell carcinoma, breast cancer and ovarian cancer, should be prioritized for
             enrollment

        For Part 2:

          -  Cohort A: Participants must have progressed on at least 2 prior lines of therapy

          -  Cohort B: Participants must have progressed on at least 1 prior line of platinum
             therapy and for microsatellite instability-high (MSI-H) at least 1 prior line with
             pembrolizumab

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status less than 1

          -  Tumor accessible for biopsies and agreement to conduct fresh tumor biopsies at
             Screening and before first dosing

        Exclusion Criteria:

          -  Participants not recovered from adverse events (AE) (less than or equal to Grade 1)
             related to previous therapies (excluding Grade 1 neuropathy and alopecia)

          -  Participant has a history of a second malignancy within 3 years before the date of
             enrollment

          -  Known brain metastasis

          -  Unstable angina, myocardial infarction, congestive heart failure or a coronary
             revascularization procedure within 180 days of study entry

          -  Cerebrovascular accident/stroke

          -  Diagnosis of fever within 1 week prior to study intervention administration

          -  Life expectancy of less than 4 months

          -  Steroid therapy for anti-neoplastic intent taken less than 7 days prior to the first
             dose of study intervention

          -  Major surgery within 4 weeks prior to start of study intervention

          -  Received growth factors (including erythropoietin (EPO), darbepoetin,
             granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony
             stimulating factor (GM-CSF), and platelet stimulators or transfusions within 2 weeks
             prior to the first day of study intervention